Clinical trials: SARS CoV 2 Infection
COVID-19
Effectiveness of COVID-19 Vaccine for Prevention of COVID-19 in the Dominican Republic
This study is a multisite ,grouped test-negative case-control , phase Ⅳ clinical trial of an inactivated SARS-CoV-2 vaccine (CoronaVac) manufactured by Sinovac Research and Development Co., Ltd.The purpose of this study is to…
- Trial name
- NCT04974164
- Testing
- Inactivated COVID-19 Vaccine
- Where
- 10 sites in Dominican Republic
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
Coronavirus Disease 2019 (COVID-19), Healthy Volunteer
A Study to Evaluate the Safety and Tolerability of AZD7442 in Healthy Chinese Adults
To evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AZD7442 in Healthy Chinese Adults. vs. placebo
- Trial name
- NCT05437289
- Testing
- AZD7442 IM, AZD7442 IV
- Where
- 2 sites in China
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Subjects Possibly Exposed to COVID-19
Assessment of Self-Collected Sample Compared to Clinician Collected Sample in COVID-19 and Influenza Program
We are trying to see whether a self-collected saliva swab in the home setting is as good as or better than a study clinician-collected anterior nose swab in evaluating whether you are positive for COVID-19 or Influenza…
- Trial name
- NCT04681950
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Biocerna LLC
COVID-19
An Observational Study to Describe EVUSHELD™ (Tixagevimab/Cilgavimab) Pre-exposure Prophylaxis in Real-world Setting in Japan
This is an observational, cohort study that will use secondary data to describe the baseline demographics and clinical characteristics in patients who received EVUSHELD as PrEP against SARS-CoV-2 infection/COVID-19 in Japan.
- Trial name
- Evusheld DBR (NCT06156982)
- Testing
- Evusheld
- Where
- Japan
- Volunteers
- 397 people
- Sponsor
- AstraZeneca
COVID-19
Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant
2019nCoV-101 is a 2-part, randomized, observer-blinded, placebo-controlled, Phase 1/2 trial. Part 1 (Phase 1) of the study is designed to evaluate the safety and immunogenicity of SARS-CoV-2 rS nanoparticle vaccine with or…
- Trial name
- NCT04368988
- Testing
- SARS-CoV-2 rS - Phase 1, SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1, SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1
- Where
- 18 sites in United States, Australia
- Volunteers
- 1,419 people, healthy volunteers welcome
- Sponsor
- Novavax
COVID-19
A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL
This is a phase 2/3, multicenter, randomized, placebo-controlled, observer-blind study assessing the safety, tolerability, immunogenicity, and efficacy of prophylactic hAd5-S-Fusion+N-ETSD against COVID-19.
- Trial name
- NCT06022224
- Testing
- hAd5-S-Fusion+N-ETSD
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- ImmunityBio, Inc.
Covid19
Clinical Trial to Assess the Efficacy and Safety of Inhaled AQ001S in the Management of Acute COVID-19 Symptoms
Double-blind parallel trial to assess the efficacy and safety of inhaled AQ001S in the management of acute COVID-19 symptoms compared.
- Trial name
- SIROCCO-1 (NCT05000346)
- Testing
- Drug, inhalation
- Where
- Belgium
- Volunteers
- 21 people
- Sponsor
- Aquilon Pharmaceuticals S.A.
Covid19, SARS (Severe Acute Respiratory Syndrome)
Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects
The study is a double-blind, randomized, placebo-controlled, multi-center, Phase 3 study to evaluate the efficacy and safety of fostamatinib in COVID-19 subjects.
- Conditions
- Covid19, SARS (Severe Acute Respiratory Syndrome), SARS Pneumonia, SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere
- Trial name
- NCT04629703
- Testing
- Fostamatinib
- Where
- 47 sites in United States, Argentina and 2 more
- Volunteers
- 280 people
- Sponsor
- Rigel Pharmaceuticals
CoronaVirus Disease-2019 (COVID-19)
Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 and IV ABBV-2B04 Given Alone and in Combination Moves Through the Body of Adult Participants With Coronavirus Disease 2019 (COVID-19)
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Lung failure is the main cause of death related to COVID-19 infection.
- Trial name
- NCT04644120
- Testing
- ABBV-47D11, ABBV-2B04
- Where
- 18 sites in United States, Hungary and 3 more
- Volunteers
- 25 people
- Sponsor
- AbbVie
COVID-19, SARS-CoV-2
Study of Self-Amplifying Messenger Ribonucleic Acid (samRNA) Vaccines Against COVID-19 in Healthy Adults and People Living With Human Immunodeficiency Virus (HIV)
The primary objective is to assess the safety and tolerability of samRNA vaccines GRT-R912, GRT-R914, and GRT-R918 when administered as prime and/or boost in healthy adult participants naïve to severe acute respiratory syndrome…
- Trial name
- NCT05435027
- Testing
- GRT-R912, samRNA-Spikebeta-TCE11, GRT-R914, samRNA-Spikebeta-TCE9, GRT-R918, samRNA-SpikeOmicron-N-TCE11
- Where
- 4 sites in South Africa
- Volunteers
- 342 people, healthy volunteers welcome
- Sponsor
- Gritstone bio, Inc.
COVID-19, SARS-CoV-2
NOWDx Test for the Detection of Antibodies to COVID-19
This study is designed to compare the performance of the NOWDx COVID-19 Test to an emergency use authorized PCR test result. The intent is to show the rapid test device is comparable to a currently marketed device.
- Conditions
- COVID-19, SARS-CoV-2, Coronavirus
- Trial name
- NCT04690413
- Testing
- NOWDx COVID-19 Test
- Where
- 3 sites in United States
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- NOWDiagnostics, Inc.
Covid19, SARS-CoV Infection
Imaging Immune Activation in COVID-19
This is a single center, single arm exploratory imaging study involving up to two intravenous microdoses of [18F]F-AraG (the second tracer dose is optional) followed by whole-body PET-CT imaging in participants with convalescent…
- Trial name
- NCT04815096
- Testing
- [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- CellSight Technologies, Inc.
COVID-19 Pneumonia
Pharmacokinetics and Safety of GST-HG171 Tablets in Subjects With Impaired and Normal Liver Function
This si a single-center, non-randomized, open, parallel, single-dose trial was designed to evaluate the safety and pharmacokinetic characteristics of GST-HG171 tablets in subjects with impaired liver function.
- Trial name
- NCT06106113
- Testing
- GST-HG171 Tablets
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Fujian Akeylink Biotechnology Co., Ltd.
Covid19
Methylation Effects of COV-19 Infection and Vaccinations
This is a retrospective non-randomized clinical study of 60 patients total to assess the effects of SARS-CoV-2 infection and the SARS-CoV-2 vaccination.
- Trial name
- NCT04939155
- Testing
- SARS-CoV-2 mRNA vaccine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- TruDiagnostic
Covid19
Gazelle COVID-19 Test Clinical Accuracy Protocol
Gazelle COVID-19 is a fluorescent lateral flow immunoassay and accompanying Reader intended for the qualitative detection of nucleocapsid antigen from SARS-CoV-2 in nasal swab specimens from individuals who are suspected of…
- Trial name
- NCT04987918
- Testing
- Applied Biosystems TaqPath COVID- 19 Combo Kit
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- Hemex Health
COVID-19
Home Usability Study of the SARS-CoV-2 (COVID-19) Test
The primary objective is to determine the usability of the SARS-CoV-2 Specimen Collection Materials for at-home collection and mailing of sample to the testing laboratory.
- Trial name
- NCT04395391
- Testing
- SARS-CoV-2
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Exact Sciences Corporation
COVID-19 Pandemic
Intranasal INNA-051 for Prevention of COVID-19 in Adults
This is a Phase 2, randomized, double-blind, placebo-controlled study of INNA-051 in adults following household contact with an individual with RT-PCR confirmed SARS CoV-2 infection.
- Trial name
- NCT05118763
- Testing
- INNA-051
- Volunteers
- healthy volunteers welcome
- Sponsor
- ENA Respiratory Pty Ltd
Coronavirus Infection, COVID
Monovalent Recombinant COVID19 Vaccine
This is a study to test a new vaccine (Covax-19) against COVID-19. COVID-19 is a potentially deadly disease that is caused by a new strain of coronavirus called SARS-CoV-2.
- Trial name
- COVAX19 (NCT04453852)
- Testing
- COVID19 vaccine, Saline
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Vaxine Pty Ltd
COVID-19, SARS-CoV-2
Study Will Assess the Safety, Neutralizing Activity and Efficacy of AZD3152 in Adults With Conditions Increasing Risk of Inadequate Protective Immune Response After Vaccination and Thus Are at High Risk of Developing Severe COVID-19
AZD3152, a single mAb, is being developed to have broad neutralizing activity across known SARS-CoV-2 variants of concern for pre-exposure prophylaxis of COVID-19.
- Trial name
- NOVELLA (NCT06057064)
- Testing
- Biological: AZD3152
- Where
- 6 sites in Russia
- Volunteers
- 116 people
- Sponsor
- AstraZeneca
COVID-19
Phase 3 Lot Consistency Study of Trivalent Hemagglutinin Nanoparticle Influenza Vaccine
Phase 3 Study Comparing Safety and Immune Response of Three Batches of Novavax Flu Vaccine in older adult participants
- Trial name
- NCT06485752
- Testing
- tNIV 1 and Matrix-M Adjuvant
- Volunteers
- healthy volunteers welcome
- Sponsor
- Novavax
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.